Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Zosteriform Porokeratosis¿¡¼­ 5-FluorouracilÀÇ Ä¡·áÈ¿°ú Therapeutic Efficacy of Topical 5-Fluorouracil for Zosteriform Porokeratosis

´ëÇÑÇǺΰúÇÐȸÁö 1977³â 15±Ç 1È£ p.63 ~ 67
±è½Ã¿ë, À̱¸ºÀ, Çã¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
±è½Ã¿ë (  ) 
°¡Å縯Àǰú´ëÇÐ ÇǺΰúÇб³½Ç

À̱¸ºÀ (  ) 
°¡Å縯Àǰú´ëÇÐ ÇǺΰúÇб³½Ç
Çã¿ø (  ) 
°¡Å縯Àǰú´ëÇÐ ÇǺΰúÇб³½Ç

Abstract


The patient, 23 year old female, with the Zosteriform Porokeratosis on right side of trunk and extrimity and a superimposed Disseminated Superficial Actinic Porokeratosis on face, was treated at Dept. of Dermatology, Catholic MedicalCoflege.
The lesions appeared at the age of 7. Her mother had similar lesions on the face and extrimities. 3% 5-Fluorouracil in Vanishing cream base was applied topically under occlusive dressing for 40 days, and the dressing was changed every 24 hours.
On seventh day erythema and papular lesion appeared, and oral administration of steroid and intermittent topical betamethasone dressing was enable to continued the occlusive dressing.
One year after the treatment the lesion did not recurred and shallow atropic scar were left with normal skin color.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS